Full history for every metric is available with a Kvantra account
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHF m | 845 | 1,102 | 1,230 | 1,271 | 1,295 | 1,328 | 1,341 | 1,423 |
| Operating profit | CHF m | 210 | 211 | ||||||
| Net profit | CHF m | 61 | 96 | 156 | 113 | 160 | 169 | 171 | 182 |
| EPS reported | CHF | 3.85 | 3.91 | ||||||
| Operating cashflow per share | CHF | 5.07 | 3.78 | ||||||
| Capex per share | CHF | 4.84 | 4.19 | ||||||
| FCF per share | CHF | 0.23 | -0.42 | ||||||
| Free cash flow | CHF m | 10.0 | -18.2 | ||||||
| Net debt | CHF m | 471 | 820 | ||||||
| Book value equity | CHF m | 1,128 | 995 | ||||||
| Book value per share | CHF | 25.78 | 22.65 | ||||||
| Number of shares | m | 43.76 | 43.92 | ||||||
| DPS (TTM paid) | CHF | 0.40 | 0.40 |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 19.38 | - | ||||||
| P/B LTM | x | 2.89 | 3.07 | ||||||
| P/S LTM | x | 2.46 | 2.28 | ||||||
| P/FCF LTM | x | 327.33 | -167.63 | ||||||
| EV/EBITDA LTM | x | 12.18 | 12.38 | ||||||
| EV/Sales LTM | x | 2.81 | 2.89 | ||||||
| Earnings Yield LTM | % | 5.16% | 5.59% | ||||||
| FCF Yield | % | 0.31% | -0.60% | ||||||
| Quality | |||||||||
| ROE | % | 14.95% | 16.14% | ||||||
| ROIC | % | 9.28% | 8.25% | ||||||
| Operating margin | % | 15.84% | 15.73% | ||||||
| Gross margin | % | 26.54% | 26.97% | ||||||
| FCF/Sales | % | 0.75% | -1.36% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +4.34% | +11.08% | ||||||
| Sales Growth YoY | % | +2.57% | +3.64% | ||||||
| Net Income Growth YoY | % | +5.37% | +11.21% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +5.56% | +7.13% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.51% | 0.59% | ||||||
| Dividend Growth | % | +5.26% | +5.26% | ||||||
| Payout Ratio | % | 9.87% | 9.86% | ||||||
| FCF/Debt | x | 0.02 | -0.02 | ||||||
| Net Debt/EBITDA | x | 1.54 | 2.62 | ||||||
| EBIT/Net interest | x | 29.47 | 19.38 | ||||||
| Net debt/market cap | % | 14.44% | 26.82% | ||||||
| Net debt/Equity | x | 0.42 | 0.82 | ||||||
| Gross debt/equity | x | 0.51 | 0.93 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free